Research & Development

We are committed to improving human health by researching and developing innovative therapies and vaccines to treat and prevent severe diseases. Our team of interdisciplinary experts (chemists, molecular biologists, virologists, immunologists, translational scientists, and clinicians) focuses on advancing treatments within oncology and infectiology. We aim to improve and extend peoples' lives by discovering new medical treatments that are effective, safe, and affordable.

Focused on advancing treatments within oncology and infectious diseases.

RocketVax

The Second-Generation, Live, and Attenuated SARS-CoV-2 Virus Vaccine RocketVax AG is a Swiss biotech startup based in Basel and was established in 2020. The company has its foundation in the ties between Swiss Rockets AG, a Swiss incubator and accelerator for startups, Gigabases Switzerland AG, a spinoff of ETH Zurich, and a team of expert scientists from the University of Basel, the University of Zurich, the ETH Zurich, the University Hospital Basel, and the Swiss Tropical and Public Health Institute in Basel. At RocketVax, we use proprietary molecular biology and chemical technology to develop novel vaccines. Our first product is RVX-13, a live, single-cycle (replication-incompetent) vaccine against SARS-CoV-2, based on breakthrough genetic engineering. Leading Swiss expert scientists from immunology and virology have joined forces to translate a novel development concept against the SARS-CoV-2 virus, a pathogen that has already impacted countless lives worldwide, into a vaccine of the next generation.

TORQUR

Torqur AG is a Swiss biotech startup launched in 2021 with the aim to deliver precise, effective, and safe targeted therapy to cancer patients worldwide. This platform is designing and developing more active and safer next-generation PI3K/mTOR inhibitors. The lead candidate is the brain penetrable drug bimiralisib (PQR309), which showed promising efficacy signals in phase I and II clinical trials in various types of cancers. TORQUR has the vision to develop efficient and affordable targeted therapies with minimal toxicity, aiming to improve the quality of life for cancer patients.